Richard Wa Luke

Title: Richard Wa Luke: Innovator in Cancer Treatment

Introduction

Richard Wa Luke is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical compounds. His work focuses on the interaction between MDM2 and p53, which is crucial in cancer biology.

Latest Patents

Richard Wa Luke holds a patent for "Piperizine-4-phenyl derivatives as inhibitors of the interaction between mdm2 and p53." This patent describes a compound of formula (1), wherein R is hydrogen, C alkyl, R CH — or R C(O)—; R is aryl, heteroaryl, heterocyclyl, aminoC alkyl, N-(C alkyl)aminoC alkyl, NN-(diC alkyl)aminoC alkyl, or R. The compounds of formula (1) inhibit the interactions between MDM2 and p53 and may be useful in the treatment of cancers.

Career Highlights

Richard Wa Luke is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to contribute to the development of innovative therapies aimed at treating various forms of cancer.

Collaborations

He has collaborated with notable colleagues such as Philip John Jewsbury and Ronald Cotton, enhancing the research and development efforts in his field.

Conclusion

Richard Wa Luke's contributions to cancer treatment through his innovative patents and collaborations highlight his importance in the pharmaceutical industry. His work continues to pave the way for advancements in cancer therapies.